> top > docs > PubMed:32907635 > annotations

PubMed:32907635 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 931-937 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T2 966-970 Body_part denotes body http://purl.org/sig/ont/fma/fma256135
T3 1274-1278 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T4 1288-1292 Body_part denotes hand http://purl.org/sig/ont/fma/fma9712
T5 2140-2150 Body_part denotes lower limb http://purl.org/sig/ont/fma/fma7184
T6 2172-2177 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T7 2187-2190 Body_part denotes hip http://purl.org/sig/ont/fma/fma24964
T8 2191-2195 Body_part denotes knee http://purl.org/sig/ont/fma/fma24974
T9 2223-2234 Body_part denotes spinal cord http://purl.org/sig/ont/fma/fma7647
T10 2834-2845 Body_part denotes Haemoglobin http://purl.org/sig/ont/fma/fma62293
T11 2858-2866 Body_part denotes platelet http://purl.org/sig/ont/fma/fma62851
T12 2883-2888 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T13 3030-3035 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T14 3300-3307 Body_part denotes heparin http://purl.org/sig/ont/fma/fma82839
T15 4322-4326 Body_part denotes vein http://purl.org/sig/ont/fma/fma50723
T16 4469-4480 Body_part denotes extremities http://purl.org/sig/ont/fma/fma7182
T17 4499-4503 Body_part denotes vein http://purl.org/sig/ont/fma/fma50723

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 465-471 Body_part denotes vessel http://purl.obolibrary.org/obo/UBERON_0000055
T2 931-937 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T3 1274-1278 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T4 1288-1292 Body_part denotes hand http://purl.obolibrary.org/obo/UBERON_0002398
T5 2146-2150 Body_part denotes limb http://purl.obolibrary.org/obo/UBERON_0002101
T6 2172-2177 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T7 2187-2190 Body_part denotes hip http://purl.obolibrary.org/obo/UBERON_0001464
T8 2191-2195 Body_part denotes knee http://purl.obolibrary.org/obo/UBERON_0001465
T9 2223-2234 Body_part denotes spinal cord http://purl.obolibrary.org/obo/UBERON_0002240
T10 3030-3035 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T11 4317-4326 Body_part denotes deep vein http://purl.obolibrary.org/obo/UBERON_0035552
T12 4322-4326 Body_part denotes vein http://purl.obolibrary.org/obo/UBERON_0001638
T13 4499-4503 Body_part denotes vein http://purl.obolibrary.org/obo/UBERON_0001638

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 70-94 Disease denotes coronavirus disease-2019 http://purl.obolibrary.org/obo/MONDO_0100096
T2 384-392 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 402-415 Disease denotes viral disease http://purl.obolibrary.org/obo/MONDO_0005108
T4 472-484 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T5 809-813 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T6 926-937 Disease denotes sore throat http://purl.obolibrary.org/obo/MONDO_0002258
T7 1798-1817 Disease denotes atrial fibrillation http://purl.obolibrary.org/obo/MONDO_0004981
T8 1825-1847 Disease denotes venous thromboembolism http://purl.obolibrary.org/obo/MONDO_0005399
T9 1849-1852 Disease denotes VTE http://purl.obolibrary.org/obo/MONDO_0005399
T10 1883-1886 Disease denotes VTE http://purl.obolibrary.org/obo/MONDO_0005399
T11 1888-1911 Disease denotes acute coronary syndrome http://purl.obolibrary.org/obo/MONDO_0005542
T12 2052-2062 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T13 2128-2136 Disease denotes fracture http://purl.obolibrary.org/obo/MONDO_0005315
T14 2172-2185 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T15 2215-2234 Disease denotes trauma, spinal cord http://purl.obolibrary.org/obo/MONDO_0043797
T16 2215-2221 Disease denotes trauma http://purl.obolibrary.org/obo/MONDO_0021178
T17 2235-2241 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T18 2243-2249 Disease denotes stroke http://purl.obolibrary.org/obo/MONDO_0005098|http://purl.obolibrary.org/obo/MONDO_0011057
T20 2264-2267 Disease denotes VTE http://purl.obolibrary.org/obo/MONDO_0005399
T21 2966-2978 Disease denotes coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531
T22 2982-3000 Disease denotes bleeding diathesis http://purl.obolibrary.org/obo/MONDO_0002243
T23 3030-3043 Disease denotes liver disease http://purl.obolibrary.org/obo/MONDO_0005154
T24 3060-3072 Disease denotes coagulopathy http://purl.obolibrary.org/obo/MONDO_0001531
T25 3084-3103 Disease denotes renal insufficiency http://purl.obolibrary.org/obo/MONDO_0001106
T26 3300-3332 Disease denotes heparin-induced thrombocytopenia http://purl.obolibrary.org/obo/MONDO_0018048
T27 3316-3332 Disease denotes thrombocytopenia http://purl.obolibrary.org/obo/MONDO_0002049
T28 3343-3359 Disease denotes hypersensitivity http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271
T30 4327-4337 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T31 4371-4389 Disease denotes pulmonary embolism http://purl.obolibrary.org/obo/MONDO_0005279
T32 4391-4412 Disease denotes myocardial infarction http://purl.obolibrary.org/obo/MONDO_0005068
T33 4413-4424 Disease denotes myocarditis http://purl.obolibrary.org/obo/MONDO_0004496
T34 4435-4443 Disease denotes ischemia http://purl.obolibrary.org/obo/MONDO_0005053
T35 4504-4514 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T36 4528-4534 Disease denotes stroke http://purl.obolibrary.org/obo/MONDO_0005098|http://purl.obolibrary.org/obo/MONDO_0011057
T38 4953-4991 Disease denotes disseminated intravascular coagulation http://purl.obolibrary.org/obo/MONDO_0001243

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 113-114 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 137-138 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 158-159 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T4 189-199 http://purl.obolibrary.org/obo/BFO_0000030 denotes OBJECTIVES
T5 394-395 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T6 465-471 http://purl.obolibrary.org/obo/UBERON_0000055 denotes vessel
T7 501-511 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T8 558-559 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T9 577-582 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T10 789-790 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T11 800-804 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T12 990-994 http://purl.obolibrary.org/obo/CLO_0037284 denotes C. 4
T13 1272-1273 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T14 1274-1278 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T15 1331-1334 http://purl.obolibrary.org/obo/CLO_0002199 denotes car
T16 1631-1632 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T17 2065-2066 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T18 2146-2150 http://www.ebi.ac.uk/efo/EFO_0000876 denotes limb
T19 2172-2177 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T20 2172-2177 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T21 2172-2177 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T22 2172-2177 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T23 2187-2190 http://www.ebi.ac.uk/efo/EFO_0001929 denotes hip
T24 2223-2234 http://purl.obolibrary.org/obo/UBERON_0002240 denotes spinal cord
T25 2252-2253 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T26 2599-2600 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T27 2610-2625 http://www.ebi.ac.uk/efo/EFO_0000808 denotes anatomical site
T28 2883-2888 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T29 2922-2926 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T30 3030-3035 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T31 3030-3035 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T32 3223-3227 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T33 3479-3481 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T34 3545-3546 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T35 3991-3999 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T36 4148-4149 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T37 4269-4270 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T38 4322-4326 http://purl.obolibrary.org/obo/UBERON_0001638 denotes vein
T39 4322-4326 http://www.ebi.ac.uk/efo/EFO_0000816 denotes vein
T40 4426-4434 http://purl.obolibrary.org/obo/UBERON_0001637 denotes arterial
T41 4426-4434 http://www.ebi.ac.uk/efo/EFO_0000814 denotes arterial
T42 4469-4480 http://www.ebi.ac.uk/efo/EFO_0000876 denotes extremities
T43 4499-4503 http://purl.obolibrary.org/obo/UBERON_0001638 denotes vein
T44 4499-4503 http://www.ebi.ac.uk/efo/EFO_0000816 denotes vein
T45 5206-5207 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T46 5231-5234 http://purl.obolibrary.org/obo/CLO_0053733 denotes 1:1
T47 5538-5543 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T48 6075-6077 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T49 6492-6495 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T50 6535-6536 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 0-10 Chemical denotes Enoxaparin http://purl.obolibrary.org/obo/CHEBI_28304
T2 577-582 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T3 1293-1305 Chemical denotes disinfectant http://purl.obolibrary.org/obo/CHEBI_48219
T4 1768-1781 Chemical denotes anticoagulant http://purl.obolibrary.org/obo/CHEBI_50249
T5 3114-3124 Chemical denotes creatinine http://purl.obolibrary.org/obo/CHEBI_16737
T6 3300-3307 Chemical denotes heparin http://purl.obolibrary.org/obo/CHEBI_28304
T7 3904-3909 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T8 4077-4082 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T9 5538-5543 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T10 5748-5753 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T11 5793-5798 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T12 5966-5971 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T13 5995-6000 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T14 6518-6524 Chemical denotes Letter http://purl.obolibrary.org/obo/CHEBI_6446

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T1 472-484 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T2 489-500 http://purl.obolibrary.org/obo/GO_0050817 denotes coagulation
T3 1377-1386 http://purl.obolibrary.org/obo/GO_0006810 denotes transport
T4 3343-3359 http://purl.obolibrary.org/obo/GO_0002524 denotes hypersensitivity
T5 4980-4991 http://purl.obolibrary.org/obo/GO_0050817 denotes coagulation

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3 0-10 Chemical denotes Enoxaparin MESH:D017984
4 56-64 Species denotes patients Tax:9606
5 70-94 Disease denotes coronavirus disease-2019 MESH:C000657245
72 259-269 Chemical denotes enoxaparin MESH:D017984
73 343-351 Species denotes patients Tax:9606
74 384-392 Disease denotes COVID-19 MESH:C000657245
75 402-415 Disease denotes viral disease MESH:D001102
76 472-484 Disease denotes inflammation MESH:D007249
77 624-636 Species denotes PARTICIPANTS Tax:9606
78 667-674 Species denotes patient Tax:9606
79 752-760 Species denotes Patients Tax:9606
80 809-818 Species denotes SARS-CoV2 Tax:2697049
81 892-912 Disease denotes respiratory symptoms MESH:D012818
82 919-924 Disease denotes cough MESH:D003371
83 926-937 Disease denotes sore throat MESH:D010608
84 942-961 Disease denotes shortness of breath MESH:D004417
85 1011-1018 Species denotes patient Tax:9606
86 1153-1160 Species denotes patient Tax:9606
87 1542-1552 Chemical denotes enoxaparin MESH:D017984
88 1656-1663 Species denotes patient Tax:9606
89 1678-1688 Chemical denotes enoxaparin MESH:D017984
90 1798-1817 Disease denotes atrial fibrillation MESH:D001281
91 1825-1847 Disease denotes venous thromboembolism MESH:D054556
92 1849-1852 Disease denotes VTE MESH:D054556
93 1883-1886 Disease denotes VTE MESH:D054556
94 1981-1988 Species denotes patient Tax:9606
95 2052-2062 Disease denotes thrombosis MESH:D013927
96 2128-2136 Disease denotes fracture MESH:D050723
97 2172-2185 Disease denotes heart failure MESH:D006333
98 2187-2190 Gene denotes hip Gene:64399
99 2215-2221 Disease denotes trauma MESH:D014947
100 2223-2241 Disease denotes spinal cord injury MESH:D013119
101 2243-2249 Disease denotes stroke MESH:D020521
102 2264-2267 Disease denotes VTE MESH:D054556
103 2298-2308 Disease denotes malignancy MESH:D009369
104 2472-2480 Disease denotes bleeding MESH:D006470
105 2493-2501 Disease denotes bleeding MESH:D006470
106 2705-2713 Disease denotes bleeding MESH:D006470
107 2718-2740 Disease denotes Intracerebral bleeding MESH:D002543
108 2805-2829 Disease denotes intracranial haemorrhage MESH:D020300
109 2966-2990 Disease denotes coagulopathy or bleeding MESH:D001778
110 3030-3043 Disease denotes liver disease MESH:D008107
111 3060-3072 Disease denotes coagulopathy MESH:D001778
112 3084-3103 Disease denotes renal insufficiency MESH:D051437
113 3114-3124 Chemical denotes creatinine MESH:D003404
114 3264-3274 Chemical denotes enoxaparin MESH:D017984
115 3300-3307 Chemical denotes heparin MESH:D006493
116 3316-3332 Disease denotes thrombocytopenia MESH:D013921
117 3343-3359 Disease denotes hypersensitivity MESH:D004342
118 3501-3510 Disease denotes inability MESH:D007319
119 3608-3628 Disease denotes Cognitive impairment MESH:D003072
120 3636-3645 Disease denotes inability MESH:D007319
121 3707-3714 Species denotes Patient Tax:9606
122 3864-3872 Species denotes Patients Tax:9606
123 3936-3946 Chemical denotes enoxaparin MESH:D017984
124 4039-4047 Species denotes Patients Tax:9606
125 4196-4201 Disease denotes death MESH:D003643
126 4317-4337 Disease denotes deep vein thrombosis MESH:D020246
127 4371-4389 Disease denotes pulmonary embolism MESH:D011655
128 4391-4412 Disease denotes myocardial infarction MESH:D009203
129 4413-4424 Disease denotes myocarditis MESH:D009205
130 4426-4443 Disease denotes arterial ischemia MESH:D014715
131 4488-4514 Disease denotes splanchnic vein thrombosis MESH:D020246
132 4519-4534 Disease denotes ischemic stroke MESH:D002544
133 4814-4822 Disease denotes bleeding MESH:D006470
134 4966-4991 Disease denotes intravascular coagulation MESH:D004211
135 5097-5105 Species denotes Patients Tax:9606
136 5937-5945 Species denotes patients Tax:9606
137 6126-6133 Species denotes Patient Tax:9606

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 919-924 Phenotype denotes cough http://purl.obolibrary.org/obo/HP_0012735
T2 926-937 Phenotype denotes sore throat http://purl.obolibrary.org/obo/HP_0033050
T3 942-961 Phenotype denotes shortness of breath http://purl.obolibrary.org/obo/HP_0002098
T4 1798-1817 Phenotype denotes atrial fibrillation http://purl.obolibrary.org/obo/HP_0005110
T5 1832-1847 Phenotype denotes thromboembolism http://purl.obolibrary.org/obo/HP_0001907
T6 2172-2185 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T7 2243-2249 Phenotype denotes stroke http://purl.obolibrary.org/obo/HP_0001297
T8 2805-2829 Phenotype denotes intracranial haemorrhage http://purl.obolibrary.org/obo/HP_0002170
T9 2966-2978 Phenotype denotes coagulopathy http://purl.obolibrary.org/obo/HP_0003256
T10 2982-3000 Phenotype denotes bleeding diathesis http://purl.obolibrary.org/obo/HP_0001892
T11 3030-3043 Phenotype denotes liver disease http://purl.obolibrary.org/obo/HP_0001392
T12 3060-3072 Phenotype denotes coagulopathy http://purl.obolibrary.org/obo/HP_0003256
T13 3084-3103 Phenotype denotes renal insufficiency http://purl.obolibrary.org/obo/HP_0000083
T14 3300-3332 Phenotype denotes heparin-induced thrombocytopenia http://purl.obolibrary.org/obo/HP_0011874
T15 3343-3359 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T16 3608-3628 Phenotype denotes Cognitive impairment http://purl.obolibrary.org/obo/HP_0100543
T17 4317-4337 Phenotype denotes deep vein thrombosis http://purl.obolibrary.org/obo/HP_0002625
T18 4371-4389 Phenotype denotes pulmonary embolism http://purl.obolibrary.org/obo/HP_0002204
T19 4391-4412 Phenotype denotes myocardial infarction http://purl.obolibrary.org/obo/HP_0001658
T20 4413-4424 Phenotype denotes myocarditis http://purl.obolibrary.org/obo/HP_0012819
T21 4488-4514 Phenotype denotes splanchnic vein thrombosis http://purl.obolibrary.org/obo/HP_0030247
T22 4519-4534 Phenotype denotes ischemic stroke http://purl.obolibrary.org/obo/HP_0002140
T23 4953-4991 Phenotype denotes disseminated intravascular coagulation http://purl.obolibrary.org/obo/HP_0005521

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-188 Sentence denotes Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
T2 189-200 Sentence denotes OBJECTIVES:
T3 201-512 Sentence denotes The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
T4 513-526 Sentence denotes TRIAL DESIGN:
T5 527-623 Sentence denotes The OVID study is conducted as a multicentre open-label superiority randomised controlled trial.
T6 624-637 Sentence denotes PARTICIPANTS:
T7 638-659 Sentence denotes Inclusion Criteria 1.
T8 660-748 Sentence denotes Signed patient informed consent after being fully informed about the study's background.
T9 749-751 Sentence denotes 2.
T10 752-876 Sentence denotes Patients aged 50 years or older with a positive test for SARS-CoV2 in the past 5 days and eligible for ambulatory treatment.
T11 877-879 Sentence denotes 3.
T12 880-992 Sentence denotes Presence of respiratory symptoms (i.e. cough, sore throat, or shortness of breath) or body temperature >37.5° C.
T13 993-995 Sentence denotes 4.
T14 996-1174 Sentence denotes Ability of the patient to travel to the study centre by private transportation, performed either by an accompanying person from the same household or by the patient themselves 5.
T15 1175-1306 Sentence denotes Ability to comply with standard hygiene requirements at the time of in-hospital visit, including a face mask and hand disinfectant.
T16 1307-1309 Sentence denotes 6.
T17 1310-1501 Sentence denotes Ability to walk from car to study centre or reach it by wheelchair transport with the help of an accompanying person from the same household also complying with standard hygiene requirements.
T18 1502-1504 Sentence denotes 7.
T19 1505-1689 Sentence denotes Ability to self-administer prefilled enoxaparin injections after instructions received at the study centre or availability of a person living with the patient to administer enoxaparin.
T20 1690-1711 Sentence denotes Exclusion Criteria 1.
T21 1712-1912 Sentence denotes Any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior venous thromboembolism (VTE), acute confirmed symptomatic VTE, acute coronary syndrome.
T22 1913-1915 Sentence denotes 2.
T23 1916-2067 Sentence denotes Anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis:  a.
T24 2068-2444 Sentence denotes Any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke,  b. previous VTE,  c. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable.
T25 2445-2447 Sentence denotes 3.
T26 2448-2714 Sentence denotes Any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding.
T27 2715-2717 Sentence denotes 4.
T28 2718-2830 Sentence denotes Intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial haemorrhage.
T29 2831-2833 Sentence denotes 5.
T30 2834-2938 Sentence denotes Haemoglobin <8 g/dL and platelet count <50 x 109 cells/L confirmed by recent laboratory test (<90 days).
T31 2939-2941 Sentence denotes 6.
T32 2942-3073 Sentence denotes Subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy.
T33 3074-3076 Sentence denotes 7.
T34 3077-3239 Sentence denotes Severe renal insufficiency (baseline creatinine clearance <30 mL/min calculated using the Cockcroft-Gault formula) confirmed by recent laboratory test (<90 days).
T35 3240-3242 Sentence denotes 8.
T36 3243-3360 Sentence denotes Contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity.
T37 3361-3363 Sentence denotes 9.
T38 3364-3405 Sentence denotes Current use of dual antiplatelet therapy.
T39 3406-3409 Sentence denotes 10.
T40 3410-3478 Sentence denotes Participation in other interventional studies over the past 30 days.
T41 3479-3482 Sentence denotes 11.
T42 3483-3603 Sentence denotes Non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.
T43 3604-3607 Sentence denotes 12.
T44 3608-3706 Sentence denotes Cognitive impairment and/or inability to understand information provided in the study information.
T45 3707-3834 Sentence denotes Patient enrolment will take place at seven Swiss centres, including five university hospitals and two large cantonal hospitals.
T46 3835-3863 Sentence denotes INTERVENTION AND COMPARATOR:
T47 3864-4038 Sentence denotes Patients randomized to the intervention group will receive subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days.
T48 4039-4115 Sentence denotes Patients randomized to the comparator group will receive no anticoagulation.
T49 4116-4130 Sentence denotes MAIN OUTCOMES:
T50 4131-4244 Sentence denotes Primary outcome: a composite of any hospitalization or all-cause death occurring within 30 days of randomization.
T51 4245-5081 Sentence denotes SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment.
T52 5082-5096 Sentence denotes RANDOMISATION:
T53 5097-5158 Sentence denotes Patients will undergo block stratified randomization (by age:
T54 5159-5276 Sentence denotes 50-70 vs. >70 years; and by study centre) with a randomization ratio of 1:1 with block sizes varying between 4 and 8.
T55 5277-5504 Sentence denotes Randomization will be performed after the signature of the informed consent for participation and the verification of the eligibility criteria using the electronic data capture software (REDCAP, Vanderbilt University, v9.1.24).
T56 5505-5524 Sentence denotes BLINDING (MASKING):
T57 5525-5587 Sentence denotes In this open-label study, no blinding procedures will be used.
T58 5588-5627 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T59 5628-5709 Sentence denotes The sample size calculation is based on the parameters α = 0.05 (2-sided), power:
T60 5710-5812 Sentence denotes 1-β = 0.8, event rate in experimental group, pexp = 0.09 and event rate in control group, pcon = 0.15.
T61 5813-5852 Sentence denotes The resulting total sample size is 920.
T62 5853-6001 Sentence denotes To account for potential dropouts, the total sample size was fixed to 1000 with 500 patients in the intervention group and 500 in the control group.
T63 6002-6015 Sentence denotes TRIAL STATUS:
T64 6016-6052 Sentence denotes Protocol version 1.0, 14 April 2020.
T65 6053-6109 Sentence denotes Protocol version 3.0, 18 May 2020 Recruiting start date:
T66 6110-6120 Sentence denotes June 2020.
T67 6121-6145 Sentence denotes Last Patient Last Visit:
T68 6146-6157 Sentence denotes March 2021.
T69 6158-6177 Sentence denotes TRIAL REGISTRATION:
T70 6178-6234 Sentence denotes ClinicalTrials.gov Identifier: NCT04400799 First Posted:
T71 6235-6267 Sentence denotes May 26, 2020 Last Update Posted:
T72 6268-6296 Sentence denotes July 16, 2020 FULL PROTOCOL:
T73 6297-6405 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T74 6406-6586 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-188 Sentence denotes Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
T2 189-200 Sentence denotes OBJECTIVES:
T3 201-512 Sentence denotes The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
T4 513-526 Sentence denotes TRIAL DESIGN:
T5 527-623 Sentence denotes The OVID study is conducted as a multicentre open-label superiority randomised controlled trial.
T6 624-637 Sentence denotes PARTICIPANTS:
T7 638-659 Sentence denotes Inclusion Criteria 1.
T8 660-748 Sentence denotes Signed patient informed consent after being fully informed about the study's background.
T9 749-751 Sentence denotes 2.
T10 752-876 Sentence denotes Patients aged 50 years or older with a positive test for SARS-CoV2 in the past 5 days and eligible for ambulatory treatment.
T11 877-879 Sentence denotes 3.
T12 880-992 Sentence denotes Presence of respiratory symptoms (i.e. cough, sore throat, or shortness of breath) or body temperature >37.5° C.
T13 993-995 Sentence denotes 4.
T14 996-1174 Sentence denotes Ability of the patient to travel to the study centre by private transportation, performed either by an accompanying person from the same household or by the patient themselves 5.
T15 1175-1306 Sentence denotes Ability to comply with standard hygiene requirements at the time of in-hospital visit, including a face mask and hand disinfectant.
T16 1307-1309 Sentence denotes 6.
T17 1310-1501 Sentence denotes Ability to walk from car to study centre or reach it by wheelchair transport with the help of an accompanying person from the same household also complying with standard hygiene requirements.
T18 1502-1504 Sentence denotes 7.
T19 1505-1689 Sentence denotes Ability to self-administer prefilled enoxaparin injections after instructions received at the study centre or availability of a person living with the patient to administer enoxaparin.
T20 1690-1711 Sentence denotes Exclusion Criteria 1.
T21 1712-1912 Sentence denotes Any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior venous thromboembolism (VTE), acute confirmed symptomatic VTE, acute coronary syndrome.
T22 1913-1915 Sentence denotes 2.
T23 1916-2067 Sentence denotes Anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis:  a.
T24 2068-2444 Sentence denotes Any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke,  b. previous VTE,  c. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable.
T25 2445-2447 Sentence denotes 3.
T26 2448-2714 Sentence denotes Any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding.
T27 2715-2717 Sentence denotes 4.
T28 2718-2830 Sentence denotes Intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial haemorrhage.
T29 2831-2833 Sentence denotes 5.
T30 2834-2938 Sentence denotes Haemoglobin <8 g/dL and platelet count <50 x 109 cells/L confirmed by recent laboratory test (<90 days).
T31 2939-2941 Sentence denotes 6.
T32 2942-3073 Sentence denotes Subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy.
T33 3074-3076 Sentence denotes 7.
T34 3077-3239 Sentence denotes Severe renal insufficiency (baseline creatinine clearance <30 mL/min calculated using the Cockcroft-Gault formula) confirmed by recent laboratory test (<90 days).
T35 3240-3242 Sentence denotes 8.
T36 3243-3360 Sentence denotes Contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity.
T37 3361-3363 Sentence denotes 9.
T38 3364-3405 Sentence denotes Current use of dual antiplatelet therapy.
T39 3406-3409 Sentence denotes 10.
T40 3410-3478 Sentence denotes Participation in other interventional studies over the past 30 days.
T41 3479-3482 Sentence denotes 11.
T42 3483-3603 Sentence denotes Non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.
T43 3604-3607 Sentence denotes 12.
T44 3608-3706 Sentence denotes Cognitive impairment and/or inability to understand information provided in the study information.
T45 3707-3834 Sentence denotes Patient enrolment will take place at seven Swiss centres, including five university hospitals and two large cantonal hospitals.
T46 3835-3863 Sentence denotes INTERVENTION AND COMPARATOR:
T47 3864-4038 Sentence denotes Patients randomized to the intervention group will receive subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days.
T48 4039-4115 Sentence denotes Patients randomized to the comparator group will receive no anticoagulation.
T49 4116-4130 Sentence denotes MAIN OUTCOMES:
T50 4131-4244 Sentence denotes Primary outcome: a composite of any hospitalization or all-cause death occurring within 30 days of randomization.
T51 4245-5081 Sentence denotes SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment.
T52 5082-5096 Sentence denotes RANDOMISATION:
T53 5097-5158 Sentence denotes Patients will undergo block stratified randomization (by age:
T54 5159-5276 Sentence denotes 50-70 vs. >70 years; and by study centre) with a randomization ratio of 1:1 with block sizes varying between 4 and 8.
T55 5277-5504 Sentence denotes Randomization will be performed after the signature of the informed consent for participation and the verification of the eligibility criteria using the electronic data capture software (REDCAP, Vanderbilt University, v9.1.24).
T56 5505-5524 Sentence denotes BLINDING (MASKING):
T57 5525-5587 Sentence denotes In this open-label study, no blinding procedures will be used.
T58 5588-5627 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T59 5628-5709 Sentence denotes The sample size calculation is based on the parameters α = 0.05 (2-sided), power:
T60 5710-5812 Sentence denotes 1-β = 0.8, event rate in experimental group, pexp = 0.09 and event rate in control group, pcon = 0.15.
T61 5813-5852 Sentence denotes The resulting total sample size is 920.
T62 5853-6001 Sentence denotes To account for potential dropouts, the total sample size was fixed to 1000 with 500 patients in the intervention group and 500 in the control group.
T63 6002-6015 Sentence denotes TRIAL STATUS:
T64 6016-6052 Sentence denotes Protocol version 1.0, 14 April 2020.
T65 6053-6109 Sentence denotes Protocol version 3.0, 18 May 2020 Recruiting start date:
T66 6110-6120 Sentence denotes June 2020.
T67 6121-6145 Sentence denotes Last Patient Last Visit:
T68 6146-6157 Sentence denotes March 2021.
T69 6158-6177 Sentence denotes TRIAL REGISTRATION:
T70 6178-6234 Sentence denotes ClinicalTrials.gov Identifier: NCT04400799 First Posted:
T71 6235-6267 Sentence denotes May 26, 2020 Last Update Posted:
T72 6268-6296 Sentence denotes July 16, 2020 FULL PROTOCOL:
T73 6297-6405 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T74 6406-6586 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
T1 0-188 Sentence denotes Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
T2 189-200 Sentence denotes OBJECTIVES:
T3 201-512 Sentence denotes The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
T4 513-526 Sentence denotes TRIAL DESIGN:
T5 527-623 Sentence denotes The OVID study is conducted as a multicentre open-label superiority randomised controlled trial.
T6 624-637 Sentence denotes PARTICIPANTS:
T7 638-659 Sentence denotes Inclusion Criteria 1.
T8 660-748 Sentence denotes Signed patient informed consent after being fully informed about the study's background.
T9 749-751 Sentence denotes 2.
T10 752-876 Sentence denotes Patients aged 50 years or older with a positive test for SARS-CoV2 in the past 5 days and eligible for ambulatory treatment.
T11 877-879 Sentence denotes 3.
T12 880-992 Sentence denotes Presence of respiratory symptoms (i.e. cough, sore throat, or shortness of breath) or body temperature >37.5° C.
T13 993-995 Sentence denotes 4.
T14 996-1174 Sentence denotes Ability of the patient to travel to the study centre by private transportation, performed either by an accompanying person from the same household or by the patient themselves 5.
T15 1175-1306 Sentence denotes Ability to comply with standard hygiene requirements at the time of in-hospital visit, including a face mask and hand disinfectant.
T16 1307-1309 Sentence denotes 6.
T17 1310-1501 Sentence denotes Ability to walk from car to study centre or reach it by wheelchair transport with the help of an accompanying person from the same household also complying with standard hygiene requirements.
T18 1502-1504 Sentence denotes 7.
T19 1505-1689 Sentence denotes Ability to self-administer prefilled enoxaparin injections after instructions received at the study centre or availability of a person living with the patient to administer enoxaparin.
T20 1690-1711 Sentence denotes Exclusion Criteria 1.
T21 1712-1912 Sentence denotes Any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior venous thromboembolism (VTE), acute confirmed symptomatic VTE, acute coronary syndrome.
T22 1913-1915 Sentence denotes 2.
T23 1916-2067 Sentence denotes Anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis:  a.
T24 2068-2444 Sentence denotes Any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke,  b. previous VTE,  c. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable.
T25 2445-2447 Sentence denotes 3.
T26 2448-2714 Sentence denotes Any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding.
T27 2715-2717 Sentence denotes 4.
T28 2718-2830 Sentence denotes Intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial haemorrhage.
T29 2831-2833 Sentence denotes 5.
T30 2834-2938 Sentence denotes Haemoglobin <8 g/dL and platelet count <50 x 109 cells/L confirmed by recent laboratory test (<90 days).
T31 2939-2941 Sentence denotes 6.
T32 2942-3073 Sentence denotes Subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy.
T33 3074-3076 Sentence denotes 7.
T34 3077-3239 Sentence denotes Severe renal insufficiency (baseline creatinine clearance <30 mL/min calculated using the Cockcroft-Gault formula) confirmed by recent laboratory test (<90 days).
T35 3240-3242 Sentence denotes 8.
T36 3243-3360 Sentence denotes Contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity.
T37 3361-3363 Sentence denotes 9.
T38 3364-3405 Sentence denotes Current use of dual antiplatelet therapy.
T39 3406-3409 Sentence denotes 10.
T40 3410-3478 Sentence denotes Participation in other interventional studies over the past 30 days.
T41 3479-3482 Sentence denotes 11.
T42 3483-3603 Sentence denotes Non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.
T43 3604-3607 Sentence denotes 12.
T44 3608-3706 Sentence denotes Cognitive impairment and/or inability to understand information provided in the study information.
T45 3707-3834 Sentence denotes Patient enrolment will take place at seven Swiss centres, including five university hospitals and two large cantonal hospitals.
T46 3835-3863 Sentence denotes INTERVENTION AND COMPARATOR:
T47 3864-4038 Sentence denotes Patients randomized to the intervention group will receive subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days.
T48 4039-4115 Sentence denotes Patients randomized to the comparator group will receive no anticoagulation.
T49 4116-4130 Sentence denotes MAIN OUTCOMES:
T50 4131-4244 Sentence denotes Primary outcome: a composite of any hospitalization or all-cause death occurring within 30 days of randomization.
T51 4245-5081 Sentence denotes SECONDARY OUTCOMES: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment.
T52 5082-5096 Sentence denotes RANDOMISATION:
T53 5097-5158 Sentence denotes Patients will undergo block stratified randomization (by age:
T54 5159-5276 Sentence denotes 50-70 vs. >70 years; and by study centre) with a randomization ratio of 1:1 with block sizes varying between 4 and 8.
T55 5277-5504 Sentence denotes Randomization will be performed after the signature of the informed consent for participation and the verification of the eligibility criteria using the electronic data capture software (REDCAP, Vanderbilt University, v9.1.24).
T56 5505-5524 Sentence denotes BLINDING (MASKING):
T57 5525-5587 Sentence denotes In this open-label study, no blinding procedures will be used.
T58 5588-5627 Sentence denotes NUMBERS TO BE RANDOMISED (SAMPLE SIZE):
T59 5628-5709 Sentence denotes The sample size calculation is based on the parameters α = 0.05 (2-sided), power:
T60 5710-5812 Sentence denotes 1-β = 0.8, event rate in experimental group, pexp = 0.09 and event rate in control group, pcon = 0.15.
T61 5813-5852 Sentence denotes The resulting total sample size is 920.
T62 5853-6001 Sentence denotes To account for potential dropouts, the total sample size was fixed to 1000 with 500 patients in the intervention group and 500 in the control group.
T63 6002-6015 Sentence denotes TRIAL STATUS:
T64 6016-6052 Sentence denotes Protocol version 1.0, 14 April 2020.
T65 6053-6109 Sentence denotes Protocol version 3.0, 18 May 2020 Recruiting start date:
T66 6110-6120 Sentence denotes June 2020.
T67 6121-6145 Sentence denotes Last Patient Last Visit:
T68 6146-6157 Sentence denotes March 2021.
T69 6158-6177 Sentence denotes TRIAL REGISTRATION:
T70 6178-6234 Sentence denotes ClinicalTrials.gov Identifier: NCT04400799 First Posted:
T71 6235-6267 Sentence denotes May 26, 2020 Last Update Posted:
T72 6268-6296 Sentence denotes July 16, 2020 FULL PROTOCOL:
T73 6297-6405 Sentence denotes The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
T74 6406-6586 Sentence denotes In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.